Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer

Brain metastases (BM) occur in approximately 30% of patients with stage III non-small cell lung cancer (NSCLC) in the first two years after diagnosis and have a devastating impact on survival and quality of life[1]. The 5-year overall survival (OS) of unresectable stage III NSCLC patients who receive concurrent chemoradiotherapy ranges between approximately 24% and 32%[2].

Source: Radiotherapy and Oncology - February 12, 2021 Category: Radiology Authors: Willem J.A. Witlox, Bram L.T. Ramaekers, Benjamin Lacas, Cecile Le Pechoux, Jean-Pierre Pignon, Alexander Sun, Si-Yu Wang, Chen Hu, Mary Redman, Vincent van der Noort, Ning Li, Matthias Guckenberger, Harm van Tinteren, Harry J.M. Groen, Manuela A. Joore, Tags: Original Article Source Type: research